Summary Mutations in the WAFJ/CIPJ gene were not found in 36 ovarian carcinomas, including tumours with loss of heterozygosity at the WAFJ/CIPI locus and/or lacking p53 mutations. In addition, no association was demonstrable between a polymorphism in a conserved region of the WAFI/CIPI gene and ovarian carcinoma
The p21 protein is a cyclin-dependent kinase (CDK) inhibitor encoded by the WAFI/CIP1 gene (Harper et al., 1993; Xiong et al., 1993; El-Deiry et al., 1993) . It is a mediator of p53 (ElDeiry et al., 1993 (ElDeiry et al., , 1994 , a tumour-suppressor gene mutated in a wide variety of tumours (Hollstein et al., 1991) . It provides a link between cell cycle regulation and p53 expression, as its induction by p53 results in inhibition of cyclin/CDK-mediated phosphorylation of retinoblastoma (RB) protein. The latter is required for GI to S transition (Harper et al., 1993; El-Deiry et al., 1993) . WAFJ/CIPI may have additional roles in cell cycle regulation and cancer because it can also be induced by a p53-independent pathway (Michieli et al., 1994) and is able to inhibit DNA replication and repair independently of the CDKs (Waga et al., 1994; Li et al., 1994) .
It was proposed that mutations in the WAFI/CIPI gene may contribute to the development of ovarian tumours lacking p53 mutations (El-Deiry et al., 1993) , as these tumours frequently show losses of heterozygosity in a region of chromosome 6p that includes the WAFJ/CIP] locus (Cliby et al., 1993; Foulkes et al., 1993; Wan et al., 1994) . A tumour-suppressor role for p21 is further supported by the fact that its expression inhibits the growth of cultured tumour cells (El-Deiry et al., 1993) . The finding of point mutations in ovarian tumours with loss of heterozygosity involving the WAFJ/CIP1 locus, especially in the absence of p53 mutations, would strongly support a role for this gene as a tumour suppressor important for the control of ovarian tumorigenesis. We therefore sequenced the WAFJ/CIP1 gene in ovarian tumours already characterised for the presence or absence of loss of heterozygosity at this locus and for p53 mutations.
Materials and methods
Source and handling of tissue and blood samples All tumours were of ovarian epithelial origin. The source and handling procedures were described previously (Wan et al., 1994) . DNA from normal individuals was extracted from white blood cells obtained from volunteers of mixed ethnic origins but with a predominance of those of Hispanic origin.
Mutational analysis of WAF1/CIPI gene
The entire exon 2 and the 5' portion of exon 3 of the WAFII CIP] gene were enzymatically amplified from genomic DNA using intron-based primers (obtained from Dr Bert Vogelstein, Baltimore, MD, USA). The sense and antisense primers used for amplification of exon 2 were 5'-TGGAAGGAGT-GAGAGAGA-3' and 5'-ATCCTGGTCCCTTACAAAGT-3' respectively. Sense and antisense primers for amplification of the 5' portion of exon 3 were 5'-GGCAGCTCCGCCGC-GTCC-3' and 5'-CGCGCTTCCAGGACTGCAGG-3'. The amplification products from exon 3 were reamplified using the following sense nested primer: 5'-CTTCTTGGCCTGG-CTGAC-3'. Annealing temperatures were 1°C below the lowest primer melting temperature, as calculated using Gene Jockey software (Biosoft, Cambridge, UK, version 1.20). The PCR products were electrophoresed on 1 % agarose gels. The resulting bands were excised, purified using a Qiaex Kit (Qiagen, Chatsworth, CA, USA), and sequenced directly using the Sequenase 2.0 Kit (US Biochemicals, Cleveland, OH, USA) following protocols recommended by the manufacturers. The products were electrophoresed on 6% polyacrylamide gels under denaturing conditions. The sense primers used for direct sequencing of enzymatically amplified exon 2 were: 5'-CGCCATGTCAGAACCG-3', 5'-ATGGA-ACTTCGACTTTGTCA-3' and 5'-AAGACCATGTGGAC-CTGTCA-3'. Antisense sequencing primers for exon 2 were: 5'-GTCATGCTGGTCTGCCGCCG-3', 5'-AAGTCACCCT-CCAGTGGTGT-3' and 5'-AGACAGTGACAGGTCCA-CAT-3'. The exon 3 amplification primers were also used as sequencing primers for this exon.
Loss of heterozygosity determinations and documentation of p53 mutations Loss of heterozygosity and p53 mutation analyses were reported previously in these tumour samples (Wan et al., 1994; Zheng et al., 1995) .
Statistical analyses Differences between two proportions were calculated using Fisher's exact test. All P-values are double-sided.
Results
We sequenced the entire coding region of the WAFI/CIPJ gene in 36 ovarian carcinomas. Such mutations were not found in any of these tumours, which included 18 carcinomas not harbouring any p53 mutations and 14 with loss of heterozygosity on chromosome 6p (Table I) . A single nucleotide substitution, involving codon 31 of the WAFI/ CIPI gene (AGC to AGA), was observed in 12 (33%) tumours (Table I ). This substitution, changing the predicted amino acid from serine to arginine, was concordant in the Correspondence: L Dubeau Received 5 September 1995; revised 5 December 1995; accepted 3 January 1996 WAF1/CIP1 mutation in ovarian carcinomas M Wan et a! patients' normal cells and therefore constitutes a polymorphism rather than a mutation, in agreement with Chedid et al. (1994) . Six of the 12 cases showing this polymorphism contained p53 mutations and four showed loss of heterozygosity on chromosome 6p. Thus, there was no correlation between presence of the polymorphism and either p53 mutations (P= 1.3) or allelic loss on chromosome 6p (P= 0.7). We sequenced 27 blood DNA samples obtained from normal individuals to determine whether this polymorphism was associated with increased cancer predisposition. The Arg3l allele was found in 10 of the 27 (37%) normal individuals, indicating that its frequency in the normal population was not different from that of patients with ovarian carcinomas (P=0.8).
Discussion
The results of our experiments clearly show that WAFJ/CIPI mutations are rare in ovarian carcinomas, including those tumours with allelic losses at the WAFJ/CIP1 locus and those tumours without p53 mutations. These results are therefore not compatible with the idea that mutational inactivation of the WAFJ/CIPI gene is important for the control of ovarian tumorigenesis. Recently published studies (Shiohara et One possibility is that these authors studied different tumour types including tumours of mesench-mal origin but did not examine ovarian carcinomas. In addition. it is not known if the p53 mutations that they examined were similar to those present in our tumour population. There is growing e'vidence supporting the notion that derangements in cell cycle control play an important role in tumour development (Hartw-ell and Kastan. 1994: Hunter. 1993) . Further evidence for such derangements in ovarian tumours comes from the apparent constituti've expression of the RB gene in these tumours (Kim et al.. 1994 : Dodson et al.. 1994 . Mutations in the p53 gene. which are frequent in ov-arian tumours (Zheng et al.. 1995) . may account for such expression in some cases. Structural abnormalities in one or se,veral other mediators of cell cycle activity must be present in the remaining cases. However. mutations in the RB gene itself are infrequent in these tumours (Kim et al.. 1994: 
